We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: bimekizumab
MedXY News
EnglishTag

bimekizumab

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa: Efficacy, Safety, and Economic Assessments
Clinical UpdatesbiologicsCost-Effectiveness

Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa: Efficacy, Safety, and Economic Assessments

By MedXY|Aug 11, 2026

This review synthesizes current evidence on adalimumab, secukinumab, and bimekizumab for moderate-to-severe hidradenitis suppurativa, emphasizing clinical efficacy, safety, mechanistic insights, and cost-effectiveness across diverse health

Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program
Clinical Updatesbimekizumab
clinical trials

Long-term Efficacy and Safety of Bimekizumab in Moderate-to-Severe Hidradenitis Suppurativa: A 2-Year Synthesis of the BE HEARD Clinical Program

By MedXY|Mar 6, 2026

This review synthesizes 2-year results from the BE HEARD phase 3 trials and their extension, demonstrating that dual IL-17A/F inhibition with bimekizumab provides deep, durable clinical responses and a favorable safety profile for patients

Bimekizumab Sustains Complete Skin Clearance and Quality of Life Improvements Through Three Years in Plaque Psoriasis: Insights from the BE RADIANT Trial
Dermatologybimekizumabplaque psoriasis

Bimekizumab Sustains Complete Skin Clearance and Quality of Life Improvements Through Three Years in Plaque Psoriasis: Insights from the BE RADIANT Trial

By MedXY|Feb 19, 2026

The BE RADIANT trial demonstrates that bimekizumab provides rapid, superior, and durable skin clearance (PASI 100) and symptom relief compared to secukinumab over three years, with a manageable safety profile and significant quality-of-life

Dual IL-17A/F Blockade and Increased Candidiasis Risk
Clinical Updatesbimekizumab

Dual IL-17A/F Blockade and Increased Candidiasis Risk

By MedXY|Sep 30, 2025

Blocking both IL-17A and IL-17F impairs neutrophil migration, reducing antifungal defense and raising candidiasis risk in patients on bimekizumab, according to in vitro evidence.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities